A5090769354- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Ocular Oncology and Treatments
- Lung Cancer Research Studies
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Nonmelanoma Skin Cancer Studies
- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Nanoplatforms for cancer theranostics
- Immune Cell Function and Interaction
- Ferroptosis and cancer prognosis
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- Immune cells in cancer
- Blood groups and transfusion
- Synthesis and biological activity
- Computational Drug Discovery Methods
Duke University
2016-2025
Duke Medical Center
2016-2025
Duke Cancer Institute
2015-2025
Duke University Hospital
2013-2025
Cancer Institute (WIA)
2014-2024
Duke University Health System
2021-2023
Regeneron (United States)
2021
Vanderbilt-Ingram Cancer Center
2021
Moffitt Cancer Center
2021
Breast Cancer Research Foundation
2021
In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with high rate objective response, including complete responses, among patients advanced melanoma.
Uveal melanoma is a disease that distinct from cutaneous melanoma, with low tumor mutational burden and 1-year overall survival of approximately 50% in patients metastatic uveal melanoma. Data showing proven benefit systemic treatment are lacking. Tebentafusp bispecific protein consisting an affinity-enhanced T-cell receptor fused to anti-CD3 effector can redirect T cells target glycoprotein 100-positive cells.In this open-label, phase 3 trial, we randomly assigned previously untreated...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes rationale supporting extensive changes recommendations systemic therapy as adjuvant treatment of resected disease unresectable or distant metastatic disease.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to recommendations 2016 update. Depending stage options now include biochemotherapy high-dose ipilimumab. Treatment disease intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment data supporting older recommended resulting...
Over the past few years, NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways treatment of microscopic satellitosis (added in v2.2020), and following Principles sections: Molecular Testing v2.2019), Systemic Therapy Considerations Brain Metastases Management v3.2020). The v1.2021 update included additional modifications these sections notable revisions of: Pathology, Surgical Margins Wide Excision Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic...
Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.A multi-institutional, retrospective cohort analysis identified adults advanced melanoma who received treatment nivolumab or pembrolizumab as standard clinical practice through expanded access programs published...
PURPOSE BRAF V600 mutations are commonly found in melanoma and thyroid cancers to a lesser degree other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought investigate selective inhibitor dabrafenib MEK1/2 trametinib patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored mutation. PATIENTS AND METHODS EAY131-H is an open-label, single-arm study. Patients melanoma, thyroid, colorectal cancer were excluded; non–small-cell lung later excluded...
An in-depth understanding of immune escape mechanisms in cancer is likely to lead innovative advances immunotherapeutic strategies. However, much remains unknown regarding these and how they impact immunotherapy resistance. Using several preclinical tumor models as well clinical specimens, we identified a mechanism whereby CD8+ T cell activation response programmed death 1 (PD-1) blockade induced ligand 1/NOD-, LRR-, pyrin domain-containing protein 3 (PD-L1/NLRP3) inflammasome signaling...
Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive HLA-A*02:01 have unresectable or metastatic uveal melanoma. The primary analysis in the present phase 3 trial supported long-term survival benefit associated with drug.
The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations diagnostic workup, staging, and treatment of patients. These Insights focus on the update to neoadjuvant systemic therapy options summarize new clinical data evaluated by panel recommended therapies in Version 2.2024 Melanoma.
Cancer immunotherapy relies on the ability of immune system to target tumor-specific antigens generate an response. This initial response requires both binding MHC/antigen peptide T-cell receptor complex, along with a second costimulatory signal created by CD28 T cell, B7 located antigen-presenting cell. Regulatory checkpoints, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), serve attenuate this signal, thereby preventing autoimmunity. Its key role in regulating has made CTLA-4...
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These Insights summarize rationale supporting extensive changes recommendations systemic therapy patients with metastatic or unresectable melanoma.
<h3>Background</h3> Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the clinic. We currently unable to predict which patients will develop severe toxicities associated with these regimens. <h3>Case presentation</h3> present patient stage IV melanoma that developed rapid onset autoimmune type 1 diabetes (T1D) response combination ipilimumab...
While immune checkpoint blockade is associated with prolonged responses in multiple cancers, most patients still do not benefit from this therapeutic strategy. The Wnt-β-catenin pathway diminished T cell infiltration; however, activating mutations are rare, implicating a role for autocrine/paracrine Wnt ligand-driven signaling evasion. In study, we show that proximal mediators of the anti-PD-1 resistance, and pharmacologic inhibition ligand supports efficacy by reversing dendritic...
Background While programmed cell death protein 1 (PD-1) and death-ligand (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following entry via poliovirus receptor CD155, which expressed on tumor antigen-presenting cells. Preclinical studies show oncolytic virus plus anti-PD-1 therapy leads to greater than either agent alone,...
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) 38% 31%45%) pembrolizumab mg/kg, compared with 16% 10%-22%) the arm. by investigator assessment similar to that of central review. effect consistent in all subgroups. ORR 21% at 25% 4% arm (P<0.0001 Median response duration not reached either 37 weeks Forty-eight percent patients crossed treatment. OS data are mature (final analysis will be performed after 370 deaths...
BackgroundIn KEYNOTE-002, pembrolizumab significantly prolonged progression-free survival and was associated with a better safety profile compared chemotherapy in patients advanced melanoma that progressed after ipilimumab. We present health-related quality of life (HRQoL) outcomes from KEYNOTE-002.MethodsPatients were randomly assigned 1:1:1 to 2 or 10 mg/kg every 3 weeks (Q3W) investigator-choice chemotherapy. HRQoL assessed using the European Organisation for Research Treatment Cancer...